BIOMAT Database Logo BIOMAT Database Logo

A molecular mucosal adjuvant to enhance immunity against pneumococcal infection in the elderly. 2015

Yoshiko Fukuyama, and Yorihiko Ikeda, and Junichiro Ohori, and Gen Sugita, and Kazuyoshi Aso, and Keiko Fujihashi, and David E Briles, and Jerry R McGhee, and Kohtaro Fujihashi
Division of Mucosal Immunology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

Streptococcus pneumoniae (the pneumococcus) causes a major upper respiratory tract infection often leading to severe illness and death in the elderly. Thus, it is important to induce safe and effective mucosal immunity against this pathogen in order to prevent pnuemocaccal infection. However, this is a very difficult task to elicit protective mucosal IgA antibody responses in older individuals. A combind nasal adjuvant consisting of a plasmid encoding the Flt3 ligand cDNA (pFL) and CpG oligonucleotide (CpG ODN) successfully enhanced S. pneumoniae-specific mucosal immunity in aged mice. In particular, a pneumococcal surface protein A-based nasal vaccine given with pFL and CpG ODN induced complete protection from S. pneumoniae infection. These results show that nasal delivery of a combined DNA adjuvant offers an attractive potential for protection against the pneumococcus in the elderly.

UI MeSH Term Description Entries

Related Publications

Yoshiko Fukuyama, and Yorihiko Ikeda, and Junichiro Ohori, and Gen Sugita, and Kazuyoshi Aso, and Keiko Fujihashi, and David E Briles, and Jerry R McGhee, and Kohtaro Fujihashi
A nontoxic adjuvant for mucosal immunity to pneumococcal surface protein A.
October 1998, Journal of immunology (Baltimore, Md. : 1950),
Yoshiko Fukuyama, and Yorihiko Ikeda, and Junichiro Ohori, and Gen Sugita, and Kazuyoshi Aso, and Keiko Fujihashi, and David E Briles, and Jerry R McGhee, and Kohtaro Fujihashi
Is the oral microbiome a source to enhance mucosal immunity against infectious diseases?
June 2021, NPJ vaccines,
Yoshiko Fukuyama, and Yorihiko Ikeda, and Junichiro Ohori, and Gen Sugita, and Kazuyoshi Aso, and Keiko Fujihashi, and David E Briles, and Jerry R McGhee, and Kohtaro Fujihashi
Preclinical Development of Virulence-attenuated Streptococcus pneumoniae Strains Able to Enhance Protective Immunity against Pneumococcal Infection.
April 2021, American journal of respiratory and critical care medicine,
Yoshiko Fukuyama, and Yorihiko Ikeda, and Junichiro Ohori, and Gen Sugita, and Kazuyoshi Aso, and Keiko Fujihashi, and David E Briles, and Jerry R McGhee, and Kohtaro Fujihashi
Mucosal immunization with caseinolytic protease X elicited cross-protective immunity against pneumococcal infection in mice.
June 2012, Experimental biology and medicine (Maywood, N.J.),
Yoshiko Fukuyama, and Yorihiko Ikeda, and Junichiro Ohori, and Gen Sugita, and Kazuyoshi Aso, and Keiko Fujihashi, and David E Briles, and Jerry R McGhee, and Kohtaro Fujihashi
Non-mucosal vaccination strategies to enhance mucosal immunity.
July 2023, Vaccine insights,
Yoshiko Fukuyama, and Yorihiko Ikeda, and Junichiro Ohori, and Gen Sugita, and Kazuyoshi Aso, and Keiko Fujihashi, and David E Briles, and Jerry R McGhee, and Kohtaro Fujihashi
Type IIb Heat Labile Enterotoxin B Subunit as a Mucosal Adjuvant to Enhance Protective Immunity against H5N1 Avian Influenza Viruses.
November 2020, Vaccines,
Yoshiko Fukuyama, and Yorihiko Ikeda, and Junichiro Ohori, and Gen Sugita, and Kazuyoshi Aso, and Keiko Fujihashi, and David E Briles, and Jerry R McGhee, and Kohtaro Fujihashi
Preclinical Efficacy of a Trivalent Human FcγRI-Targeted Adjuvant-Free Subunit Mucosal Vaccine against Pulmonary Pneumococcal Infection.
April 2020, Vaccines,
Yoshiko Fukuyama, and Yorihiko Ikeda, and Junichiro Ohori, and Gen Sugita, and Kazuyoshi Aso, and Keiko Fujihashi, and David E Briles, and Jerry R McGhee, and Kohtaro Fujihashi
The nontoxic CTA1-DD adjuvant enhances protective immunity against Helicobacter pylori infection following mucosal immunization.
February 2006, Scandinavian journal of immunology,
Yoshiko Fukuyama, and Yorihiko Ikeda, and Junichiro Ohori, and Gen Sugita, and Kazuyoshi Aso, and Keiko Fujihashi, and David E Briles, and Jerry R McGhee, and Kohtaro Fujihashi
Prospects for use of interleukin-12 as a mucosal adjuvant for vaccination of humans to protect against respiratory pneumococcal infection.
September 2008, Vaccine,
Yoshiko Fukuyama, and Yorihiko Ikeda, and Junichiro Ohori, and Gen Sugita, and Kazuyoshi Aso, and Keiko Fujihashi, and David E Briles, and Jerry R McGhee, and Kohtaro Fujihashi
The mucosal adjuvant effect of plant polysaccharides for induction of protective immunity against Helicobacter pylori infection.
February 2019, Vaccine,
Copied contents to your clipboard!